Rapt Therapeutics Stock Performance
| RAPT Stock | USD 1.26 0.03 2.44% |
The firm holds a Beta of 2.87, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, RAPT Therapeutics will likely underperform. At this point, RAPT Therapeutics has a negative expected return of -0.34%. Please make sure to check RAPT Therapeutics' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if RAPT Therapeutics performance from the past will be repeated at future time.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days RAPT Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
1 | RAPT stock touches 52-week low at 1.76 amid sharp annual decline - Investing.com | 09/23/2024 |
2 | Acquisition by Robbins Wendye of 600 shares of RAPT Therapeutics at 19.95 subject to Rule 16b-3 | 10/09/2024 |
3 | Brokerages Set RAPT Therapeutics, Inc. PT at 18.17 | 10/28/2024 |
4 | RAPT scraps zelnecirnon program, stock plunges 44 | 11/11/2024 |
5 | Stifel cuts Rapt Therapeutics target to 2, downgrades to hold | 11/12/2024 |
6 | Disposition of 75000 shares by Dirk Brockstedt of RAPT Therapeutics at 24.75 subject to Rule 16b-3 | 11/13/2024 |
7 | What is Leerink Partnrs Estimate for RAPT FY2024 Earnings | 11/14/2024 |
| Begin Period Cash Flow | 38.9 M |
RAPT |
RAPT Therapeutics Relative Risk vs. Return Landscape
If you would invest 202.00 in RAPT Therapeutics on September 2, 2024 and sell it today you would lose (76.00) from holding RAPT Therapeutics or give up 37.62% of portfolio value over 90 days. RAPT Therapeutics is currently does not generate positive expected returns and assumes 8.4265% risk (volatility on return distribution) over the 90 days horizon. In different words, 75% of stocks are less volatile than RAPT, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
RAPT Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for RAPT Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as RAPT Therapeutics, and traders can use it to determine the average amount a RAPT Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0406
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RAPT |
Estimated Market Risk
| 8.43 actual daily | 75 75% of assets are less volatile |
Expected Return
| -0.34 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average RAPT Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of RAPT Therapeutics by adding RAPT Therapeutics to a well-diversified portfolio.
RAPT Therapeutics Fundamentals Growth
RAPT Stock prices reflect investors' perceptions of the future prospects and financial health of RAPT Therapeutics, and RAPT Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on RAPT Stock performance.
| Return On Equity | -0.8 | ||||
| Return On Asset | -0.47 | ||||
| Current Valuation | (48.74 M) | ||||
| Shares Outstanding | 34.96 M | ||||
| Price To Book | 0.46 X | ||||
| Price To Sales | 411.22 X | ||||
| Gross Profit | 1.53 M | ||||
| EBITDA | (125.85 M) | ||||
| Net Income | (116.8 M) | ||||
| Cash And Equivalents | 207.34 M | ||||
| Cash Per Share | 6.99 X | ||||
| Total Debt | 6.91 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 15.97 X | ||||
| Book Value Per Share | 2.74 X | ||||
| Cash Flow From Operations | (97.05 M) | ||||
| Earnings Per Share | (2.78) X | ||||
| Market Capitalization | 44.05 M | ||||
| Total Asset | 173.33 M | ||||
| Retained Earnings | (484.68 M) | ||||
| Working Capital | 139.95 M | ||||
| Current Asset | 17 K | ||||
| Current Liabilities | 167 K | ||||
About RAPT Therapeutics Performance
Assessing RAPT Therapeutics' fundamental ratios provides investors with valuable insights into RAPT Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the RAPT Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.67) | (0.71) | |
| Return On Capital Employed | (0.84) | (0.88) | |
| Return On Assets | (0.67) | (0.71) | |
| Return On Equity | (0.79) | (0.83) |
Things to note about RAPT Therapeutics performance evaluation
Checking the ongoing alerts about RAPT Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for RAPT Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| RAPT Therapeutics generated a negative expected return over the last 90 days | |
| RAPT Therapeutics has high historical volatility and very poor performance | |
| RAPT Therapeutics may become a speculative penny stock | |
| RAPT Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (116.8 M) with profit before overhead, payroll, taxes, and interest of 1.53 M. | |
| RAPT Therapeutics currently holds about 207.34 M in cash with (97.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.99, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 87.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: What is Leerink Partnrs Estimate for RAPT FY2024 Earnings |
- Analyzing RAPT Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether RAPT Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining RAPT Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating RAPT Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of RAPT Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of RAPT Therapeutics' stock. These opinions can provide insight into RAPT Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for RAPT Stock Analysis
When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.